PRODUCT

Retatrutide (40 MG)

No short description available.

Quickstart Highlights

Retatrutide is a triple agonist of the GLP-1, GIP, and glucagon receptors, developed to support significant weight reduction and improve metabolic control. It is administered once weekly by subcutaneous injection, starting with a low dose and gradually increasing it to improve gastrointestinal tolerability.

Reconstitution: Add 3.0 mL of bacteriostatic water → approximately 10.0 mg/mL concentration.
Dose Range: 2–12 mg once weekly with gradual increases every 4 weeks.
Easy Measuring: At a concentration of 10.0 mg/mL, 1 unit = 0.01 mL = 0.1 mg (100 mcg) on a U-100 insulin syringe.
Storage: Store lyophilized powder at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 4 weeks.

Reconstitution

Draw 3.0 mL of bacteriostatic water using a sterile syringe.
Slowly inject the liquid down the inside wall of the vial to minimize foaming.
Gently swirl or roll the vial until the powder has completely dissolved (do not shake).
Label the vial with the reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Use the solution within 4 weeks after reconstitution.

Protocol Overview

Goal:Support significant weight reduction and metabolic improvement through the simultaneous activation of GLP-1, GIP, and glucagon receptors.
Schedule:One subcutaneous injection per week for 12–48 weeks.
Dose Range:2–12 mg per week with dose increases every 4 weeks.
Reconstitution:3.0 mL per 30 mg vial (≈ 10.0 mg/mL) for accurate dosing.
Storage:Store the lyophilized product frozen; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) for up to 4 weeks.

Dosage Protocols

Start:2 mg por semana durante as primeiras 4 semanas para avaliar a tolerância.
Escalation:Aumentar 2–4 mg a cada 4 semanas, conforme a resposta individual.
Target:6–8 mg por semana como faixa padrão; até 12 mg por semana em protocolos avançados.
Frequency:Uma aplicação por semana (via subcutânea), sempre no mesmo dia.
Protocol Duration:Mínimo de 24 semanas; em estudos clínicos, foi estendido por até 48 semanas.
Timing:Qualquer dia e horário consistentes; alternar os locais de aplicação.

Storage Instructions

Lyophilized:Store at −20 °C (−4 °F) or colder in a dry, dark place. Stable for up to 24 months.
Reconstituted:Refrigerate at 2–8 °C (35.6–46.4 °F) and use within 4 weeks.

Benefits and Side Effects

Benefits

Significant weight loss, with average reductions of 22–24% of body weight after 48 weeks at 8–12 mg doses.
Improved glycemic control, with significant reductions in HbA1c in people with type 2 diabetes.
Improvements in blood pressure, LDL cholesterol, waist circumference, and liver fat.
In clinical studies, nearly all participants receiving higher doses achieved at least 5% body-weight reduction.

Side Effects

Nausea, vomiting, and diarrhea were the most common adverse effects, particularly during dose escalation.
These effects were generally mild to moderate and decreased with gradual titration.
No severe treatment-related hypoglycemia episodes were observed in the clinical studies.
The safety profile was comparable to other GLP-1 agonists when appropriate dose escalation was followed.

Important Notes

Practical considerations for maintaining consistency and safety.

Use a new sterile insulin syringe for each injection and dispose of it in a sharps container.
Use a new sterile insulin syringe for each injection and dispose of it in a sharps container.
Inject slowly and steadily; wait a few seconds before withdrawing the needle.
Keep a record of the weekly dose, date, and injection site to maintain consistency.
Follow gradual dose escalation and do not increase the dose faster than the established schedule.
Monitor for gastrointestinal symptoms such as nausea, vomiting, or diarrhea, particularly during dose escalation.

How It Works

Retatrutide is a triple agonist designed to simultaneously activate the GLP-1, GIP, and glucagon receptors. Activation of GLP-1 and GIP promotes insulin secretion when glucose levels are elevated, reduces appetite, and increases feelings of satiety. Meanwhile, activation of the glucagon receptor increases energy expenditure and promotes the use of fat as an energy source. Due to its modified structure, retatrutide has an approximate 6-day half-life, allowing once-weekly administration. The combination of these three mechanisms reduces caloric intake, increases energy expenditure, and improves glycemic control.

Lifestyle Factors

Maintain a balanced, protein-rich diet with adequate vitamins and minerals to help preserve lean mass.
Combine resistance training 2–3 times per week with regular aerobic exercise.
Aim for 7–9 hours of sleep per night and manage stress.
Maintain adequate hydration, especially if gastrointestinal symptoms occur.
Undergo regular medical monitoring to evaluate glucose, HbA1c, lipid profile, and liver function.

Injection Technique

Clean the vial stopper and skin with alcohol and allow them to dry completely.
Pinch a fold of skin and insert the needle at a 45–90° angle.
Do not aspirate during subcutaneous injections; inject slowly and steadily.
If the volume exceeds 1.0 mL, divide the dose into two injections at different sites.
Systematically rotate injection sites (abdomen, thighs, and upper arms) to help prevent lipohypertrophy.
Wait a few seconds before withdrawing the needle to help ensure complete dose delivery.
Immediately dispose of the syringe in a sharps container.

Retatrutide (40 MG)

Resources

Categories

Company